Navigation Links
TNFerade(TM) Phase III Data Presented at ASCO
Date:6/1/2009

GAITHERSBURG, Md., June 1 /PRNewswire-FirstCall/ -- Overall survival data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) were presented yesterday at the 45th American Society of Clinical Oncology Annual Meeting in Orlando, FL.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

The poster, entitled "Multi-Center Randomized Controlled Phase III Clinical Trial using TNFerade(TM) with Chemoradiation in Patients with Locally Advanced Pancreatic Cancer: Interim Analysis of Overall Survival," reported on results of an interim analysis from the PACT trial. This interim analysis of overall survival was conducted after the 92nd death (one-third of total expected events) had occurred.

The analysis concluded that TNFerade appeared to be safe and well-tolerated. The analysis also indicated a 25% reduction in the risk of death in the TNFerade plus standard-of-care (SOC) arm compared to the patients receiving SOC alone (Hazard Ratio = 0.75; 95% Confidence Interval [0.494 - 1.15]).

Dr. Mark Thornton, GenVec's Senior Vice President of Product Development commented on the poster, noting, "In the SOC patients, 75% of the patients died within approximately 11.8 months. However, in the TNFerade plus SOC group, 75% of the patients did not die until approximately 19.4 months. Although the data still need time and events to reach maturity, we are encouraged by the survival trend being observed at this point in the trial."

This poster can be accessed online by visiting www.genvec.com and clicking on "Investor Relations" then "Webcasts & Data" then "Data Presentations."

About PACT

GenVec's PACT trial is a multi-center, randomized, active, and controlled study of 330 patients designed to evaluate the safety and efficacy of TNFerade plus standard of care versus standard of care alone in patients with locally advanced pancreatic cancer. The next interim analysis is expected to occur after two-thirds of the events (or 184 deaths) have occurred in the trial. Results are expected to be announced in early 2010.

About TNFerade(TM)

TNFerade, which has not yet been approved for use, is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF alpha in the tumor. TNFerade has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
4. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
11. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... -- Transparency Market Research has released a new market ... Alcohol and Others) Market - Global Industry Analysis, Size, Share, Growth, ... benzaldehyde derivative market was valued at US$ 1.37 Bn in ... expanding at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are ...
(Date:1/17/2017)... BUDAPEST, Hungary , Jan. 17, 2017 /PRNewswire/ ... Plc. today announced positive results from Venus II, the second ... and safety of ulipristal acetate in women with abnormal bleeding ... ulipristal acetate is planned for the second half of 2017. ... Venus II supporting the efficacy and safety profile of ulipristal ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ago the ... Education program forged a relationship built upon the foundation of sports safety. ... of both student members and certified members of the Athletic Trainers’ Society of ...
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium ... East Hanover, New Jersey. , “We are elated to be opening this new showroom,” ... is designed to give clients a seamless and motivating shopping experience.” , Every fitness ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... office , Antoine Dental Center, is currently offering complimentary consultations and financing for ... their teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, ...
Breaking Medicine News(10 mins):